Comments
Aurobindo Pharma’s wholly-owned subsidiary company, Eugia Pharma Specialities Limited, has received the final approval from the US Food and Drug Administration (USFDA) for Amphotericin B Liposome for Injection.
The approved product, Amphotericin B Liposome for Injection, is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), AmBisome Liposome for Injection, of Astellas Pharma US, Inc.
The product is expected to be launched by Q4 FY23. The approved product has an estimated market size of around $145 million for the twelve months ending September 2022, according to IQVIA.
It is indicated in the treatment of fungal infections.
Related Stories
Aurobindo Pharma shares tumble nearly 7% in early trade; hit 52-week low after Q2 earnings
Aurobindo Pharma’s shares plunge 6.52% to ₹457.20 on the BSE, while it declined 6.60% to ₹457 at the NSE
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.